Panbela Therapeutics, Inc. (PBLA)
OTCMKTS: PBLA · Delayed Price · USD
0.610
-0.065 (-9.60%)
Mar 28, 2024, 3:36 PM EDT - Market closed
Panbela Therapeutics Stock Forecast
PBLA's stock price has decreased by -99.79% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for PBLA stock have an average target of 172.5, with a low estimate of 25 and a high estimate of 320. The average target predicts an increase of 28,178.69% from the current stock price of 0.61.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for PBLA stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Roth MKM | Roth MKM | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +3,998.36% | Mar 27, 2024 |
Roth MKM | Roth MKM | Strong Buy Maintains $500 → $25 | Strong Buy | Maintains | $500 → $25 | +3,998.36% | Feb 5, 2024 |
Roth MKM | Roth MKM | Strong Buy Reiterates $500 | Strong Buy | Reiterates | $500 | +81,867.21% | Dec 18, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +52,359.02% | Aug 11, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +52,359.02% | Jul 24, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-207.94
from -1.26K
EPS Next Year
-35.07
from -207.94
Revenue Forecast
Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | n/a | n/a | n/a | 22.4M | 116.1M | 361.2M |
Avg | n/a | n/a | n/a | 15.2M | 74.2M | 218.2M |
Low | n/a | n/a | n/a | 8.2M | 34.2M | 82.1M |
Revenue Growth
Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | 665.9% | 386.9% |
Avg | - | - | - | - | 389.4% | 194.1% |
Low | - | - | - | - | 125.7% | 10.7% |
EPS Forecast
EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | -204.33 | -5.22 | -5.71 | -1.90 | 1.34 | 11.89 |
Avg | -207.94 | -35.07 | -31.03 | -2.84 | 0.27 | 5.96 |
Low | -208.87 | -62.52 | -54.29 | -3.68 | -0.74 | 0.35 |
EPS Growth
EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|---|
High | - | - | - | - | - | 4,381.9% |
Avg | - | - | - | - | - | 2,146.2% |
Low | - | - | - | - | - | 33.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.